These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25575025)

  • 1. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
    Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
    Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.
    Sayan M; Sargin F; Inan D; Sevgi DY; Celikbas AK; Yasar K; Kaptan F; Kutlu S; Fisgin NT; Inci A; Ceran N; Karaoglan I; Cagatay A; Celen MK; Koruk ST; Ceylan B; Yildirmak T; Akalın H; Korten V; Willke A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):26-31. PubMed ID: 26414663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
    Pham HT; Mesplède T; Wainberg MA
    Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
    Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
    J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
    Cherry E; Morin N; Wainberg MA
    AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model.
    Pingen M; Sarrami-Forooshani R; Wensing AM; van Ham P; Drewniak A; Boucher CA; Geijtenbeek TB; Nijhuis M
    Retrovirology; 2014 Dec; 11():113. PubMed ID: 25499671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance.
    Pérez-Alvarez L; Carmona R; Muñoz M; Delgado E; Thomson MM; Contreras G; Pedreira JD; Rodríguez Real R; Vázquez de Parga E; Medrano L; Taboada JA; Nájera R;
    Antivir Ther; 2003 Aug; 8(4):355-60. PubMed ID: 14518705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
    García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
    J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.
    Pessôa R; Sanabani SS
    PLoS One; 2017; 12(9):e0185559. PubMed ID: 28953964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.
    Suñé C; Brennan L; Stover DR; Klimkait T
    Clin Microbiol Infect; 2004 Feb; 10(2):119-26. PubMed ID: 14759236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
    Pingen M; Nijhuis M; Mudrikova T; van Laarhoven A; Langebeek N; Richter C; Boucher CA; Wensing AM
    J Antimicrob Chemother; 2015 Feb; 70(2):573-80. PubMed ID: 25261422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
    Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
    J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
    van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
    J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered replicative capacity of recombinant HIV type 1 containing mutations at codons 26 and 29 of the viral protease.
    Melón S; Gil-Roda C; de Oña M; Erice A
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1183-8. PubMed ID: 15588340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
    Moscona R; Ram D; Wax M; Bucris E; Levy I; Mendelson E; Mor O
    J Int AIDS Soc; 2017 Aug; 20(1):21846. PubMed ID: 28799325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.